Theravance Biopharma has announced the appointment of former Roche Partnering VP Shehnaaz Suliman as Senior VP, Corporate Development and Strategy.
Theravance Biopharma Chairman and CEO Rick E. Winningham commented, “We are thrilled to add an individual of Dr. Suliman’s impressive accomplishments, leadership and energy to our senior team. Her successes in the areas of corporate and business development, product licensing and program management strategy at global leaders such as Roche, Genentech and Gilead speak for themselves. With a growing portfolio of novel therapeutics across several interesting indications and various stages of development, we are fortunate to strengthen our team with Dr. Suliman’s unique insight and expertise.”
Suliman said, “I have a keen appreciation for the impressive success that Theravance Biopharma has achieved in creating a rich pipeline of internally discovered therapeutics. The company’s deep commitment to excellent science and patient care has resulted in innovative product candidates with differentiated profiles intended to deliver meaningful benefit to patients across a number of high unmet need disease categories. I look forward to joining the Theravance Biopharma team and applying my experience to the goal of maximizing the value of the company’s therapeutic portfolio to significantly enhance and impact patient care.”
Read the Theravance Biopharma press release.
